ABL1 and interstitial lung disease: Yang et al. (28) investigated amiodarone-associated pulmonary adverse events, Cortes et al. (29) examined cardiopulmonary toxicities related to BCR-ABL inhibitors, and Jiang et al. (30) analyzed drug-induced interstitial lung disease (DIILD) - a condition that is pathophysiologically distinct from DIPE.